Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezagepras in T2DM with Metabolic Syndrome
NCT03081598Phase 2Terminated
- Sponsor
- Liminal BioSciences Inc.
- Start
- May 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fezagepras in type 2 diabetes mellitus (T2DM), metabolic syndrome, sponsored by Liminal BioSciences Inc.. Started May 2017; status: terminated.
02
Drugs
fezagepras
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic syndrome
Beyond the preview
Go deeper on NCT03081598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081598.